Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
Health Science
There’s nothing more terrifying than watching a loved one pause, clutch their throat and start gasping for air. The first time it happens provokes the mad scramble, as she…
Death & children’s novels When I think about Amanita Muscaria the first two things that come to mind are death, and children’s novels. Amanita Muscaria is arguably the…
Fulcrum Therapeutics (FULC.Q) announced positive results today from its ongoing Phase 1 trial with FTX-6058 in healthy adult volunteers. “We are very pleased with the interim results from this…
Revive Therapeutics (RVV.C) provided an update on their psychedelics development and clinical programs focused on psilocybin, which they are aiming to use to treat a number of disorders. Revive…
Bioasis Technologies (BTI.V) announces today that the Japanese Patent Office (JPO) has issued Japanese Patent No.2019-189551 Notice of Allowance for the Company’s xB3™-IDS fusion proteins. “We are excited about…
Core One Labs’ (COOL.C) wholly-owned subsidiary Akome Biotech announced they are initiating the next step of their clinical development of their patent-pending psychedelic formulations AKO001 and AKO003. The next…
Axsome Therapeutics (AXSM.Q) announced today that its AXS-05 has met primary and key secondary endpoints in the MERIT (Mechanistic Evaluation of Response in TDR) Phase 2 trial. Additionally, the…
“What sector is hot?” is the one question I get asked more than any other. Well, okay, maybe “Why didn’t you respond to my text?” is the most asked,…
Forget weed crypto First off, most all of those crypto/cannabis hybrid deals were super cringe, and I never saw the point of combining the two, at least not at…